新锐医药（股票代码：06108）公布截至二零二五年十二月三十一日止年度业绩。集团在报告期内录得收入约1.304亿元港元，较上一年度的0.939亿元港元增长约38.9%。相应毛利约0.161亿元港元，同比上升约40%。尽管收入与毛利均有提升，集团全年仍录得净亏损约0.201亿元港元，较上一年度收窄约35.2%。董事会建议不派付本年度之末期股息。
业务方面，医药及相关产品分销及贸易分部在内地医改及带量采购政策的行业环境下，实现收入约1.279亿元港元，较上一年度增长约44.2%，成为集团的主要收入来源。提供营销及推广服务的收入约0.024亿元港元，较上一年度减少约53.8%，该分部收入主要来自医药产品推广及市场营销等相关服务。
集团指出，内地医药市场强调合理用药及成本控制，对分销企业的供应链效率与服务能力提出更高要求。面对带量采购和多批次药品招标带来的价格竞争以及部分抗菌药物分级管理策略的影响，集团计划持续丰富产品组合、优化分销渠道并提升营销网络，以期在未来的行业整合中抓住兼并机会，进一步加强营运能力和市场布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.